Identification and purification of a bovine corpora luteal membrane glycoprotein with [3H]prostaglandin F2-alpha binding properties

EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells

Several tetraspanins bind directly to a few molecular partners to form primary complexes, which might assemble through tetraspanin-tetraspanin interactions to form a network of molecular interactions, the tetraspanin web. We have produced a monoclonal antibody directed to a 63 kDa molecule (determined under non-reducing conditions) associated with CD9. This molecule was first identified by MS as a molecule with four Ig domains, EWI-2. Like the related molecule CD9P-1, EWI-2 was found to be a partner not only for CD9, but also for CD81, a tetraspanin required for hepatic infection by the parasite responsible for malaria, and also a putative hepatitis C virus receptor. Using chimaeric CD9/CD82 molecules, two separate regions of CD9 of 40 and 47 amino acids were demonstrated to confer the ability to interact with EWI-2. Both EWI-2 and CD9P-1 were detected in the human liver at the surface of hepatocytes and were found to associate with CD81 on freshly isolated hepatocytes. EWI-2 also co-localized with CD81 in the liver. CD9P-1 was not detected on most peripheral blood cells, whereas EWI-2 was expressed on the majority of B-, T- and natural killer cells and was not detected on monocytes, polynuclear cells or platelets. This distribution is identical to that of CD81. Finally, EWI-2 associated with all tetraspanins studied after lysis under conditions preserving tetraspanin-tetraspanin interactions, showing that EWI-2 is a new component of the tetraspanin web.

The major CD9 and CD81 molecular partner. Identification and characterization of the complexes

By associating with specific partner molecules and with each other, the tetraspanins are thought to assemble multimolecular complexes that may be especially relevant with respect to metastasis. We have previously identified a 135-kDa molecule (CD9P-1) as a major molecular partner of CD9 in cancer cell lines. This molecule was identified, after immunoaffinity purification and mass spectrometry analysis, as the protein encoded by the KIAA1436 gene and the human ortholog of a rat protein known as FPRP. Cross-linking experiments detected a complex of the size of CD9 plus CD9P-1, showing that these glycoproteins directly associate with each other, probably in the absence of any other molecule. The use of chimeric CD9/CD82 molecules revealed the role of the second half of CD9, comprising the large extracellular loop and the fourth transmembrane domain. CD9P-1 was also shown to form separate complexes with CD81 and with an unidentified 175-kDa molecule. It also associated with other tetraspanins under conditions maintaining tetraspanin/tetraspanin interactions. The identification of a protein strongly linked to the tetraspanin web and the production of a specific monoclonal antibody will help to further characterize the role of this "web" under physiological and pathological conditions.

FPRP, a major, highly stoichiometric, highly specific CD81- and CD9-associated protein

CD81 and CD9, members of the transmembrane-4 superfamily (TM4SF; tetraspanins), form extensive complexes with other TM4SF proteins, integrins, and other proteins, especially in mild detergents. In moderately stringent Brij 96 lysis conditions, CD81 and CD9 complexes are virtually identical to each other, but clearly distinct from other TM4SF complexes. One of the most prominent proteins within CD81 and CD9 complexes is identified here as FPRP, the 133-kDa prostaglandin F(2alpha) receptor regulatory protein. FPRP, a cell-surface Ig superfamily protein, associates specifically with CD81 or with CD81 and CD9, but not with integrins or other TM4SF proteins. In contrast to other CD81- and CD9-associating proteins, FPRP associates at very high stoichiometry, with essentially 100% of cell-surface FPRP on 293 cells being CD81- and CD9-associated. Also, CD81.CD9.FPRP complexes have a discrete size (<4 x 10(6) Da) as measured by gel permeation chromatography and remain intact after disruption of cholesterol-rich membrane microdomains by methyl-beta-cyclodextrin. Although CD81 associated with both alpha(3) integrin and FPRP in 293 cells, the alpha(3)beta(1).CD81 and CD81.CD9.FPRP complexes were distinct, as determined by immunoprecipitation and immunodepletion experiments. In conclusion, our data affirm the existence of distinct TM4SF complexes with unique compositions and specifically characterize FPRP as the most robust, highly stoichiometric CD81- and/or CD9-associated protein yet described.

Cloning, sequencing and proposed structure for a prostaglandin F2 alpha receptor regulatory protein

The cDNA has been cloned for a protein which copurifies with and colocalizes with [3H]PGF2 alpha binding activity, yet differs from the previously cloned prostaglandin F2 alpha receptor. Polyclonal antibody, produced against one of two protein bands present in a highly purified preparation of [3H]PGF2 alpha binding activity isolated from pregnant bovine corpus luteum, was used to screen a rat ovary cDNA expression library. A single strongly positive clone was identified containing a 4 kilobase (kb) insert. Northern analysis using this cDNA as a probe revealed the expression of a 6 kb mRNA with a tissue distribution similar to that seen by immunohistochemical analysis with the polyclonal antibody. Tissues possessing the largest quantity of the protein's mRNA are reproductive tissues, lung, and heart. Directed cDNA synthesis was required to clone the 5' end of the cDNA. Verification that the correct cDNA was cloned is provided by alignment of the predicted protein's mature amino terminal amino acid sequence with sequence observed by protein sequencing. Translation of the predicted 879 amino acid open reading frame (ORF) suggests a protein structure exhibiting six glycosylated immunoglobulin type loops, one of which may either be membrane associated or may be the site of association with another protein, a transmembrane region, and a short, highly charged, carboxy terminal cytoplasmic tail. Based upon searches of the NIH and EMBL protein databanks, this is a unique protein. The FPRP mRNA is notable for a highly structured G,C rich 5' end and over 3 kb of 3' untranslated region (UTR) that includes 7 ATTTA 'destabilization sequences' and an 'inflammatory mediator'-like sequence. These characteristic sequences in the 3' UTR suggest that the mRNA is tightly regulated and may code for a protein that is functionally related to an inflammatory mediator. Functional studies in the accompanying report suggest a negative regulatory function for this protein. We suggest the name prostaglandin F2 alpha receptor regulatory protein (FPRP).

Human chromosome 1 localization of the gene for a prostaglandin F2alpha receptor negative regulatory protein

A protein that copurifies with the bovine prostaglandin F2alpha (FP) receptor has been isolated and the corresponding rat cDNA has been cloned. Transfection experiments suggest that this protein inhibits binding of [3H]prostaglandin F2alpha ([3H]PGF2alpha) to FP. Histologically, this protein (FP regulatory protein or FPRP) shows a distribution coinciding well with those cells and tissues that respond to PGF2alpha. A portion of the 3' untranslated region of the human homolog to fprp was subcloned, sequenced, and oligonucleotide primers chosen that allow polymerase chain reaction (PCR) amplification specifically of the human fprp sequence. These primers were then used in a PCR-based mapping-protocol. The human fprp gene was first socalized through human/rodent somatic cell hybrids to human chromosome 1 (100% concordance), and further through yeast artificial chromosome (YAC) pools to region 1p13.1-q21.3 (level 1 mapping). In view of the specific histologic localization of this negative regulator, possible pathological conditions are mentioned that may cosegrepate with this chromosomal region.

Negative regulatory activity of a prostaglandin F2 alpha receptor associated protein (FPRP)

The cDNA has been cloned for a protein which copurifies with and colocalizes with [3H]PGF2 alpha binding activity. This cloning was based on prior purification of the [3H]PGF2 alpha binding complex from pregnant corpus luteum, antibody production against the protein of interest, and antibody screening of a rat ovary cDNA expression library. Here I report on the activity of this prostaglandin F2 alpha receptor (FP) associated protein (FPRP). Expression of the FPRP cDNA in COS cells results in production of a full length (approximately 130 kD) immunoreactive molecule with an endoplasmic reticulum and Golgi network distribution similar to that seen in granulosa lutein cells. COS cell expressed FPRP inhibits binding of [3H]PGF2 alpha to FP of COS cell origin or FP expressed from cotransfected rat or mouse FP cDNA in a dose-dependent manner. This inhibition of [3H]PGF2 alpha binding by FPRP occurs only when the FPRP cDNA is expressed in the same cell as the FP resides, reaches a maximum of approximately 80%, and is unaffected by second messenger perturbing agents such as phorbol ester, 8-Br-cAMP, calcium ionophore A23187, and okadaic acid. Scatchard analysis indicates that FPRP induces a decrease in receptor number rather than affinity constant, suggesting a non-competitive means of inhibition. Molecular dissection of the FPRP protein indicates that two portions of the molecule play a role in the inhibition of FP. Whether FPRP is an FP-associated regulatory molecule, an FP subunit, or a receptor for a PGF2 alpha-antagonistic ligand is presently unknown. Physiological relevance and significance of FPRP are discussed. During the course of these experiments it was necessary to clone the rat FP cDNA.

Cloning of the rat and human prostaglandin F2 alpha receptors and the expression of the rat prostaglandin F2 alpha receptor

We have cloned the FP receptor from rat corpus luteum and human uterus cDNA libraries, respectively. The coding DNA sequence in the rat cDNA is 1101 bp and is similar to the mouse cDNA coding for a receptor protein of 366 amino acids. The human sequence shows a 5 bp deficiency in the 3' region, truncating the coding sequence to 359 amino acids. Northern blot analysis indicates highest expression in the ovary. Cell lines have been established giving stable expression of the FP receptor. Activation of the cloned FP receptor gave an increase in intracellular calcium, indicating signaling via phospholipase C-mediated phosphoinositide turnover. Using [3H]PGF2 alpha, binding of PGs showed the rank order of fluprostenol > PhXA70 > PGF2 alpha > or = PhXA85 > PGD2 > PGE2.

Desensitization of prostaglandin F2 alpha receptor-mediated phosphoinositide hydrolysis in cultured rat astrocytes

Desensitization of prostaglandin (PG) F2 alpha receptor-mediated phosphoinositide (PI) hydrolysis was investigated in cultured rat astrocytes. Prolonged exposure of astrocytes differentiated by dibutyryl cyclic AMP-treatment to PGF2 alpha caused the desensitization of subsequent PGF2 alpha-induced PI hydrolysis. The desensitization was time- and PGF2 alpha dose-dependent; maximal decrease in the PI hydrolysis was observed after exposure to 10 microM PGF2 alpha for 4 h and the degree of the desensitization was 31.7 +/- 2.7% of control. Pretreatment with either PGD2 or PGE2 also induced the desensitization of subsequent PGF2 alpha-stimulated PI hydrolysis and conversely pretreatment of PGF2 alpha decreased the PI responses to PGD2 and PGE2. The desensitization prevented by phloretin and was reversible upon removal of the agonist. Protein synthesis inhibitors blocked the recovery of the desensitization. Treatment of the cells with phorbol 12-myristate 13-acetate had no effect on the desensitization. These results suggest that prolonged exposure of the astrocytes to PGF2 alpha caused the desensitization of the receptors.

Immunohistochemical localization of PGF2 alpha receptor in the rat oviduct

As a step towards understanding the role of prostaglandin F2 alpha (PGF2 alpha) in female reproductive tract physiology, a rabbit polyclonal antiserum reactive with purified PGF2 alpha receptor (PGF2 alpha-R) was produced. Here we describe use of this anti-PGF2 alpha-R antiserum in immunohistochemical staining of rat oviduct to ascertain which cell types, in vivo, possess immunoreactive PGF2 alpha-R. Western blot analysis was initially performed and confirmed that the anti-PGF2 alpha-R antiserum recognizes only one oviductal antigen. The immunopositive antigen is similar in molecular mass (by PAGE) to the previously described, purified PGF2 alpha-R molecule. Immunohistochemical staining demonstrates that adult rat oviduct contains a single subpopulation of cells with PGF2 alpha-R, and that subpopulation is a ciliated epithelial cell type found predominantly in the isthmus and distal ampullae near the isthmus-ampullae junction (I-AJ). None of these PGF2 alpha-R immunopositive cells are found in the epithelium of infundibulum oviduct. PGF2 alpha-R containing cells are not randomly distributed in the epithelium on cross-section of the isthmus and ampullae oviduct, rather, they are almost always in the crypts between infoldings of the mucosa. The relative number of this I-AJ PGF2 alpha-R containing epithelial cell subpopulation appears to vary with the phase of the rat's estrus cycle. Diestrus I-AJ epithelium contains one-half to one-third as many PGF2 alpha-R containing cells as it does in proestrus, estrus or metestrus.(ABSTRACT TRUNCATED AT 250 WORDS)

Immunohistochemical localization of PGF2 alpha receptor in the mouse testis

As a step towards understanding the role of prostaglandin F2 alpha (PGF2 alpha) in male reproductive tract physiology, a rabbit polyclonal antiserum reactive with purified PGF2 alpha receptor (PGF2 alpha-R) was produced. Here we describe the use of this anti-PGF2 alpha-R antiserum in immunohistochemical staining of mouse testis to ascertain which cell types, in vivo, possess immunoreactive PGF2 alpha-R. As an initial control Western blot analysis was performed to show that the anti-PGF2 alpha-R antiserum recognizes only one antigen in the testis, and that this molecule is similar in molecular mass (by PAGE) to the previously described, purified PGF2 alpha-R molecule. Immunohistochemical staining demonstrates that adult mouse testis contains a single subpopulation of cells with PGF2 alpha-R and that subpopulation is the interstitial or Leydig cell subpopulation. Cell and tissue types negative for immunoreactive PGF2 alpha-R include: the capsule (tunica albuginea) and subcapsular stroma, all histologic layers of the vasculature (both venules and arterioles), peritubular stroma, peritubular boundary tissue, spermatogonia, primary and secondary spermatocytes, spermatids, Sertoli cells, and spermatozoa. While the above described localization of PGF2 alpha-R is also seen in rat, there are fewer rat Leydig cells and this subpopulation appears to atrophy and stain less intensely with increasing age of the animal. Preabsorption of the PGF2 alpha-R antiserum with a corpora lutea homogenate acetone powder eliminated immunohistochemical staining of the Leydig cell subpopulation further suggesting that the antigenic determinant detected here is related to that in the ovary (PGF2 alpha-R).

Immunohistochemical localization of PGF2 alpha receptor in the rat ovary

As a step towards understanding the role of prostaglandin F2 alpha (PGF2 alpha) in ovarian function, a rabbit antiserum against purified PGF2 alpha receptor (PGF2 alpha-R) was produced. This report details the use of this antiserum in immunohistochemical staining of ovaries of non-pregnant and pregnant rats to ascertain which cell types, in vivo, possess PGF2 alpha-R. In non-pregnant rats, three ovarian cell subpopulations contain immunoreactive PGF2 alpha-R. These include: a subpopulation of the cells found in corpora lutea, a subpopulation of the thecal cells surrounding secondary and mature (Graafian) follicles, and a subpopulation of primary and secondary interstitial cells. The ovarian tissues and cell types in which immunoreactive PGF2 alpha-R cannot be demonstrated include: the serosa overlying the ovary and its vessels, the coelomic epithelium and its underlying cortical stroma, medullary stroma and vessels, granulosa cells of primary, secondary and mature follicles, the oocyte, and the blood vessels and stroma within corpora lutea. PGF2 alpha-R immunohistochemical staining of corpora lutea from non-pregnant animals was examined both prior to the start of luteolysis and during luteolysis. During luteolysis, cells undergoing apoptosis stained for the presence of PGF2 alpha-R. PGF2 alpha-R immunohistochemical staining was also examined in corpora lutea during pregnancy and until 4 days postpartum. The major findings here were the apparent large increase in staining intensity of granulosa-lutein cells during pregnancy, and the loss of PGF2 alpha-R immunopositivity of the granulosa-lutein cells during the postpartum period. In summary, three ovarian cell subpopulations, all of which can secrete steroids, possess immunoreactive PGF2 alpha-R.